Header cover image

Chinese (SSE) Life Sciences Industry Analysis

UpdatedApr 13, 2024
DataAggregated Company Financials
Companies24
  • 7D-5.1%
  • 3M-28.0%
  • 1Y-47.3%
  • YTD-29.2%

Over the last 7 days, the Life Sciences industry has dropped 5.1%, driven by a pullback from WuXi AppTec of 9.3%. On the other hand Hangzhou Tigermed Consulting is actually up 11%. However, the industry is down 47% over the past year. As for the next few years, earnings are expected to grow by 28% per annum.

Industry Valuation and Performance

Has the Chinese Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 14 Apr 2024CN¥321.2bCN¥90.3bCN¥15.0b32.4x21.4x3.6x
Tue, 12 Mar 2024CN¥362.6bCN¥90.5bCN¥15.5b33.1x23.4x4x
Thu, 08 Feb 2024CN¥350.7bCN¥91.1bCN¥16.1b27.1x21.8x3.8x
Sat, 06 Jan 2024CN¥448.6bCN¥91.1bCN¥16.1b37.1x27.9x4.9x
Mon, 04 Dec 2023CN¥533.5bCN¥91.1bCN¥16.1b38.8x33.2x5.9x
Wed, 01 Nov 2023CN¥539.3bCN¥91.9bCN¥16.6b38.4x32.5x5.9x
Fri, 29 Sep 2023CN¥520.8bCN¥92.0bCN¥18.3b35.6x28.4x5.7x
Sun, 27 Aug 2023CN¥484.4bCN¥91.8bCN¥18.7b35x25.9x5.3x
Tue, 25 Jul 2023CN¥461.0bCN¥91.3bCN¥18.5b34.9x25x5x
Thu, 22 Jun 2023CN¥455.6bCN¥91.3bCN¥18.5b33.9x24.7x5x
Sat, 20 May 2023CN¥499.3bCN¥91.3bCN¥18.5b39.4x27x5.5x
Mon, 17 Apr 2023CN¥613.5bCN¥91.2bCN¥19.1b53.3x32.1x6.7x
Wed, 15 Mar 2023CN¥585.4bCN¥85.6bCN¥20.0b49.1x29.3x6.8x
Fri, 10 Feb 2023CN¥671.6bCN¥86.6bCN¥20.8b57x32.3x7.8x
Sun, 08 Jan 2023CN¥641.9bCN¥86.6bCN¥20.8b54.2x30.8x7.4x
Tue, 06 Dec 2022CN¥592.1bCN¥86.6bCN¥20.8b50.7x28.5x6.8x
Thu, 03 Nov 2022CN¥600.6bCN¥86.5bCN¥20.8b50.5x28.9x6.9x
Sat, 01 Oct 2022CN¥536.7bCN¥78.2bCN¥16.9b44.3x31.7x6.9x
Mon, 29 Aug 2022CN¥611.6bCN¥74.6bCN¥17.0b57.5x36x8.2x
Wed, 27 Jul 2022CN¥673.0bCN¥69.0bCN¥15.2b69.6x44.3x9.8x
Fri, 24 Jun 2022CN¥627.6bCN¥69.0bCN¥15.2b62.1x41.3x9.1x
Sun, 22 May 2022CN¥601.8bCN¥68.5bCN¥15.1b55.2x39.8x8.8x
Tue, 19 Apr 2022CN¥647.7bCN¥62.7bCN¥15.0b62.1x43.2x10.3x
Thu, 17 Mar 2022CN¥597.9bCN¥62.4bCN¥14.9b58.5x40x9.6x
Sat, 12 Feb 2022CN¥533.0bCN¥57.5bCN¥12.3b62x43.3x9.3x
Mon, 10 Jan 2022CN¥676.4bCN¥57.5bCN¥12.3b79.8x54.9x11.8x
Wed, 08 Dec 2021CN¥823.3bCN¥56.9bCN¥12.1b95x67.8x14.5x
Fri, 05 Nov 2021CN¥804.1bCN¥56.9bCN¥12.1b90.8x66.2x14.1x
Sun, 03 Oct 2021CN¥1.0tCN¥55.1bCN¥12.7b111.3x78.5x18.1x
Tue, 31 Aug 2021CN¥876.4bCN¥55.1bCN¥12.7b97x68.8x15.9x
Wed, 07 Jul 2021CN¥984.9bCN¥53.4bCN¥11.5b101x85.6x18.5x
Price to Earnings Ratio

74.9x


Total Market Cap: CN¥791.1bTotal Earnings: CN¥10.6bTotal Revenue: CN¥46.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Chinese Life Sciences Industry Price to Earnings3Y Average 42.5x202220232024
Current Industry PE
  • Investors are pessimistic on the Chinese Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 21.4x which is lower than its 3-year average PE of 42.5x.
  • The 3-year average PS ratio of 9.2x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 12% per year over the last three years.
  • Revenues for these companies have grown 25% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Chinese Healthcare industry?

CN Market-2.72%
Healthcare-3.01%
Life Sciences-5.08%
Clinical Research and Equipment-5.08%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
300347 Hangzhou Tigermed ConsultingCN¥55.6810.8%
+CN¥4.7b
-47.2%PE23.8x
301333 R&G PharmaStudiesCN¥57.766.4%
+CN¥332.2m
-20.0%PE40.1x
603127 Joinn Laboratories(China)Co.LtdCN¥18.351.8%
+CN¥246.5m
-55.6%PE34.5x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

688315

CN¥13.27

Novogene

7D

-5.2%

1Y

-66.6%

688114

CN¥54.09

MGI Tech

7D

-8.3%

1Y

-42.9%

300347

CN¥55.68

Hangzhou Tigermed Consulting

7D

10.8%

1Y

-47.2%

300759

CN¥19.10

Pharmaron Beijing

7D

-6.3%

1Y

-48.4%

301333

CN¥57.76

R&G PharmaStudies

7D

6.4%

1Y

-20.0%

300463

CN¥12.30

Maccura BiotechnologyLtd

7D

-5.2%

1Y

-33.9%

688202

CN¥37.67

Shanghai Medicilon

7D

-9.6%

1Y

-72.7%

603108

CN¥18.42

Shanghai Runda Medical Technology

7D

-11.2%

1Y

38.4%

688131

CN¥32.17

Shanghai Haoyuan Chemexpress

7D

-6.0%

1Y

-63.0%